Evidence map›Paper›PMID 36838367›Full record

ArticleMicroorganisms2023

Evaluation of a Shotgun Metagenomics Approach for Detection of ESBL- and/or Carbapenemase-Producing

Pilar Lumbreras-Iglesias, Carlos Sabater, Ainhoa Fernández Moreno, Paula López de Ugarriza, Ana Fernández-Verdugo, Abelardo Margolles, María Rosario Rodicio, Teresa Bernal, Javier Fernández

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Pilar Lumbreras-IglesiasTraslational Microbiology Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0002-4312-8966
Carlos SabaterDairy Research Institute of Asturias (IPLA), Spanish National Research Council (CSIC), 33300 Villaviciosa, Spain.ORCID 0000-0002-6098-895X
Ainhoa Fernández MorenoDepartment of Hematology, Hospital Universitario Central de Asturias (HUCA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto de Oncología del Principado de Asturias (IUOPA), 33011 Oviedo, Spain.
Paula López de UgarrizaDepartment of Hematology, Hospital Universitario Central de Asturias (HUCA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto de Oncología del Principado de Asturias (IUOPA), 33011 Oviedo, Spain.
Ana Fernández-VerdugoTraslational Microbiology Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Abelardo MargollesDairy Research Institute of Asturias (IPLA), Spanish National Research Council (CSIC), 33300 Villaviciosa, Spain.
María Rosario RodicioTraslational Microbiology Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0002-3402-2908
Teresa BernalDepartment of Hematology, Hospital Universitario Central de Asturias (HUCA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto de Oncología del Principado de Asturias (IUOPA), 33011 Oviedo, Spain.ORCID 0000-0002-2338-513X
Javier FernándezTraslational Microbiology Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0002-7081-0936
Instituto de Investigación Sanitaria del Principado de Asturias · ESConsejo Superior de Investigaciones Científicas · ESHospital Universitario Central de Asturias · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESUniversidad de Oviedo · ES

Funding

European Regional Development Fund of the 229 European Union: A Way to Making EuropeInstituto de Salud Carlos III FIS PI21/01590Pfizer (Spain) Independent Scientific Research Grant
6 · The paper itself

Abstract

Patients diagnosed with acute leukemia (AL) have a weakened immune system. Infections acquired by these patients are cause for concern and especially worrisome when Gram-negative multidrug-resistant (MDR) bacteria are involved, as they are difficult to treat, especially in the case of ESBL- and/or carbapenemase-producing

Indexed as

acute leukemiacarbapenemaseEnterobacteralesESBLmetagenomics

Identifiers

PMID36838367
PMCPMC9964539
OpenAlexW4319316022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.